Advertisement

Catumaxomab

  • Giuseppe TridenteEmail author
Chapter

Abstract

Catumaxomab (Removab®, Fresenius) is a trifunctional rat-mouse hybrid monoclonal antibody co-binding to the epithelial cell adhesion molecule (EpCAM) and to CD3 antigen. The double epitope specificity allows in forcing the interaction between cancer cells expressing EpCAM, and activated T cells. The third binding via the Fc-region of catumaxomab with Fcγ receptors allows direct involvement of immune accessory cells in killing the target.

Keywords

Ovarian Cancer Systemic Inflammatory Response Syndrome Peritoneal Carcinomatosis Malignant Ascites Epithelial Cell Adhesion Molecule 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

307171_1_En_13_MOESM1_ESM.xls (60 kb)
Supplementary material 1 (XLS 61 kb)

References

  1. 1.
    Catumaxomab (Removab®) EMEA WC500051809 Annex I September 2011Google Scholar
  2. 2.
    Munz M, Baeuerle PA, Gires O (2009) The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 69:5627–5629PubMedCrossRefGoogle Scholar
  3. 3.
    Linke R, Klein A, Seimetz D (2010) Catumaxomab. Clinical development and future directions. MAbs 2:129–136Google Scholar
  4. 4.
    Frampton JE (2012) Catumaxomab in malignant ascites. Drugs 72:1399–1410PubMedCrossRefGoogle Scholar
  5. 5.
    Catumaxomab (Removab®) EMEA WC500051808 Assessment Report Feb 2009Google Scholar
  6. 6.
    Patriarca C, Macchi RM, Marschner AK et al (2012) Epithelial cell adhesion molecule expression (CD326) in cancer: a short review Cancer Treatment Rev 38:68-75Google Scholar
  7. 7.
    Burges A, Wimberger P, Kümper C et al (2007) Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clin Cancer Res 13:3899–3905PubMedCrossRefGoogle Scholar
  8. 8.
    Seimetz D (2011) Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (Removab®). J Cancer 2:309–316PubMedCrossRefGoogle Scholar
  9. 9.
    Eskander RN, Tewar KS (2012) Emerging treatment options for management of malignant ascites in patients with ovarian cancer. Intern J Women’s Health 4:395–404Google Scholar
  10. 10.
    Wimberger P, Gilet H, Gonshior A-K et al (2012) Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone. Ann Oncol 23:1979–1985PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2014

Authors and Affiliations

  1. 1.University of VeronaVeronaItaly

Personalised recommendations